Outcomes of Reinduction With Nadofaragene Firadenovec.

Saved in:
Bibliographic Details
Title: Outcomes of Reinduction With Nadofaragene Firadenovec.
Authors: Schmidt B; Huntsman Cancer Institute, Salt Lake City, Utah.; Early Career Editor, The Journal of Urology®., Horns JJ; Department of Surgery, Division of Urology, University of Utah, Salt Lake City, Utah., Tyson MD; Mayo Clinic Arizona, Scottsdale, Arizona., Daneshmand S; Department of Urology, University of Southern California, Los Angeles, California.; Western Section Representative, The Journal of Urology®., Linehan JA; Saint John's Health Center, Santa Monica, California., Agarwal PK; National Cancer Institute, Bethesda, Maryland., Narayan VM; Emory University School of Medicine, Atlanta, Georgia., Dickstein R; Chesapeake Urology Associates LLC, Hanover, Maryland., Luckenbaugh AN; Vanderbilt University Medical Center, Nashville, Tennessee., Lotan Y; The University of Texas Southwestern Medical Center, Dallas, Texas.
Source: The Journal of urology [J Urol] 2025 Nov; Vol. 214 (5), pp. 472-473. Date of Electronic Publication: 2025 Aug 25.
Publication Type: Editorial
Journal Info: Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 0376374 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-3792 (Electronic) Linking ISSN: 00225347 NLM ISO Abbreviation: J Urol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1527-3792
DOI:10.1097/JU.0000000000004697